Janus kinase inhibitor cycling may be more effective than switching to bDMARDs among patients with RA who had an inadequate response to initial JAK inhibitor therapy.

Now, two papers in Cancer Cell report a highly selective orally available JAK2 inhibitor, which shows promising ... progenitor cells (HPCs) to growth factors results in an overproduction of ...

We investigated the effects of a novel small-molecule JAK inhibitor (AZD1480 ... bone marrow (BM)-derived stromal cells and inhibits tumor growth in a Kms.11 xenograft mouse model, accompanied ...